IRIS
PIERMATTEO, LORENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.968
AS - Asia 1.604
EU - Europa 1.165
SA - Sud America 399
OC - Oceania 81
AF - Africa 40
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.259
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.892
SG - Singapore 899
IT - Italia 475
BR - Brasile 325
CN - Cina 230
HK - Hong Kong 190
DE - Germania 130
VN - Vietnam 110
GB - Regno Unito 96
IE - Irlanda 89
RU - Federazione Russa 88
AU - Australia 74
FI - Finlandia 49
ES - Italia 48
IN - India 45
CA - Canada 44
NL - Olanda 38
AR - Argentina 29
AT - Austria 29
SE - Svezia 29
PL - Polonia 25
MX - Messico 24
JP - Giappone 23
FR - Francia 22
ID - Indonesia 21
BD - Bangladesh 15
CO - Colombia 15
CZ - Repubblica Ceca 15
TR - Turchia 15
ZA - Sudafrica 11
IQ - Iraq 9
VE - Venezuela 9
EC - Ecuador 7
EG - Egitto 7
NZ - Nuova Zelanda 7
PY - Paraguay 7
UA - Ucraina 7
BE - Belgio 6
AE - Emirati Arabi Uniti 5
CH - Svizzera 5
DZ - Algeria 5
IR - Iran 5
KR - Corea 5
LT - Lituania 5
UZ - Uzbekistan 5
IL - Israele 4
JO - Giordania 4
MA - Marocco 4
PE - Perù 4
PK - Pakistan 4
CM - Camerun 3
HN - Honduras 3
MY - Malesia 3
CL - Cile 2
KE - Kenya 2
KZ - Kazakistan 2
NG - Nigeria 2
OM - Oman 2
PT - Portogallo 2
RO - Romania 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
GR - Grecia 1
HU - Ungheria 1
JM - Giamaica 1
KH - Cambogia 1
LK - Sri Lanka 1
NI - Nicaragua 1
NP - Nepal 1
PH - Filippine 1
TN - Tunisia 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZW - Zimbabwe 1
Totale 6.259
Salva come PNG Salva come JPEG
Città #
Singapore 485
Wilmington 474
Houston 306
Chandler 195
Hong Kong 190
Ashburn 163
Rome 158
Beijing 156
Fairfield 137
New York 128
Santa Clara 97
Los Angeles 92
Dublin 68
The Dalles 54
Woodbridge 54
Munich 53
Milan 51
Dallas 47
Ho Chi Minh City 46
Seattle 44
Nuremberg 42
Buffalo 40
Cambridge 38
Ann Arbor 35
Council Bluffs 33
Helsinki 32
Medford 31
La Veta 29
Melbourne 28
Hanoi 27
Sydney 27
São Paulo 26
Engelhard 25
London 24
Chicago 22
Tokyo 22
Montreal 20
Poplar 17
Redondo Beach 17
Warsaw 17
Washington 17
Canberra 16
Naples 16
Orem 16
Stockholm 16
Chennai 15
Lawrence 15
Moscow 15
Vienna 15
Genoa 14
Jakarta 14
Lappeenranta 14
Mexico City 14
Amsterdam 13
Brooklyn 13
Cedarhurst 13
Denver 13
St. George 13
Toronto 13
Madrid 12
San Francisco 12
Creede 11
San Diego 11
Bari 10
Phoenix 10
Johannesburg 9
Manchester 9
San Jose 9
Barcelona 8
Boston 8
Brno 8
Padova 8
Palo Alto 8
Rio de Janeiro 8
Auckland 7
Belo Horizonte 7
Brasília 7
Palermo 7
Pesaro 7
Ankara 6
Atlanta 6
Biên Hòa 6
Dearborn 6
Frankfurt am Main 6
Genzano di Roma 6
Guangzhou 6
Olomouc 6
Albano Laziale 5
Brussels 5
Buenos Aires 5
Charlotte 5
Fort Worth 5
Fortaleza 5
Garbagnate Milanese 5
Haiphong 5
Maceió 5
Querétaro 5
Ribeirão Preto 5
Seoul 5
Thrissur 5
Totale 4.114
Salva come PNG Salva come JPEG
Nome #
High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance 359
HDV can constrain HBV genetic evolution in hbsag: Implications for the identification of innovative pharmacological targets 320
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro 236
A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection 230
Virological reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir-sparing therapy as revealed by highly-sensitive HBV assays. 175
Quantification of intrahepatic total HBV DNA in liver biopsies of HBV-infected patients by a modified version of COBAS® Ampliprep/COBAS®TaqMan HBV test v2.0 162
Establishment of a Seronegative Occult Infection With an Active Hepatitis B Virus Reservoir Enriched of Vaccine Escape Mutations in a Vaccinated Infant After Liver Transplantation 142
Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection 138
Cryptic HBV replicative activity is frequently revealed in anti-HBC-positive/hbsag-negative patients with HIV infection by highly sensitive molecular assays, and can be predicted by integrating classical and novel serological HBV markers 134
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients 133
Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment 133
In the setting of HIV-infection, HBV-reactivation is revealed by highly sensitive assays in a conspicuous fraction of anti-HBc-positive/HBsAg-negative patients switching to Tenofovir-sparing therapy. 128
Long-term SARS-CoV-2 infection associated with viral dissemination in different body fluids Including bile in two patients with acute cholecystitis 128
Frequency of atypical mutations in the spike glycoprotein in SARS-CoV-2 circulating from July 2020 to July 2022 in central Italy: a refined analysis by Next Generation Sequencing 118
New markers in monitoring the reactivation of hepatitis B virus infection in immunocompromised hosts 111
HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation 106
Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control 105
for the Icona Foundation Study Group Reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir sparing therapy as revealed by highly sensitive HBV assays. 100
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21 98
HBcrAg tightly correlates with elevated HDV replicative activity and with enhanced liver inflammation and damage: role of HBcrAg as a biomarker of liver disease progression in the setting of HDV co-infection 85
SARS-CoV-2 variants and their relevant mutational profiles: update summer 2021 83
Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B 82
Circulation of sars-cov-2 variants in central Italy: spike variability characterization by deep-sequencing. 78
Novel concepts on mechanisms underlying Hepatitis Delta virus persistence and related pathogenesis 76
Acquisition of positively charged amino acids in HBsAg C-terminus correlates with HBV-induced liver cancer, hampers HBsAg stability and secretion and promotes cell survival 76
The acquisition of positively charged amino acids in HBsAg C-terminus correlates with HBV-induced liver cancer in vivo, impairs HBsAg secretion and affects its structural stability in vitro 71
Impact of pre-existent drug resistance on virological efficacy of single tablet regimens in people living with HIV 71
An increase in the levels of middle surface antigen characterizes patients developing HBV-driven liver cancer despite prolonged virological suppression 70
An in-depth characterization of VOCs circulation by using NGS analysis of the Spike protein. 69
Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile 68
Human monocyte-derived macrophages (MDM): model 1 (GM-CSF) 68
HUMAN ENDOGENOUS RETROVIRUSES EXPRESSION CORRELATES WITH HIV RESERVOIR, LYMPHOCYTES ACTIVATION AND LOW CD4 COUNT IN VIROLOGICALLY SUPPRESSED PATIENTS 67
ULTRASENSITIVE HBV-RNA QUANTIFICATION AS A PROMISING BIOMARKER TO OPTIMIZE THE STAGING OF CHRONIC HBV INFECTION AND TO DETECT MINIMAL VIRAL ACTIVITY UNDER PROLONGED VIROLOGICAL SUPPRESSION AND OCCULT HBV INFECTION. 67
Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies 66
Ultrasensitive HBV-RNA quantification by droplet digital PCR is a promising biomarker to optimize the staging of chronic HBV infection and to identify minimal viral activity under prolonged virological suppression. 64
HIV DNA viral reservoirs in blood and gut-associated lymphoid tissues (GALT): Implications of switch from triple antiretroviral therapy (ART) to 2-drug dolutegravir/lamivudine regimens 64
HDV replicative activity parallels the production of the three HBsAg forms (Large, Middle and Small HBsAg) and its pathogenetic impact is exacerbated by concomitant HBV replication 63
Hepatitis delta virus (HDV) infection : frequency and outcome in persons living with HIV (PLWH). Data from the ICONA (Italian cohort of naïve for antiretrovirals) cohort 63
Prevalence of hepatitis D virus infection in Central Italy has remained stable across the last 2 decades with dominance of subgenotypes 1 and characterized by elevated viral replication 62
HDV epidemic in Central Italy is stable over the last two decades and is characterized by the circulation of multiple HDV subgenotypes 1 inducing different inflammatory stimuli 62
Kinetics of HBsAg forms in chronic hepatitis delta patients treated with bulevirtide for 48 weeks: correlation with virological response 62
Evidence of extensive transcriptionally active HBV integrations involving genetic regions crucial for cell proliferation in the early phases of chronic infection even in the setting of limited liver damage 58
Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen 58
Higher levels of three HBsAg forms (Large, Middle and Small HBsAg) are associated with HDV replication and with the degree of disease and liver damage. 58
Stable temporal trend of HDV seroprevalence in central Italy across the last two decades with the circulation of HDV sub-genotypes 1 inducing different inflammatory stimuli 57
Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection 57
POTENT ANTIVIRAL ACTIVITY OF NEW GENERATION HIV-1 MATURATION INHIBITORS ON HUMAN PRIMARY CELLS 56
PREVALENCE AND OUTCOME OF HEPATITIS DELTA VIRUS (HDV) INFECTION AMONG PERSONS LIVING WITH HIV (PLWH) IN ITALY: THE DELTA-ICONA STUDY OC 150 55
The intrahepatic activity of Hepatitis Delta virus is sustained by an abundant production of HBs transcripts, mainly derived from integrated HBV-DNA, and is not strictly related to the extent of HBV reservoir 55
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort 53
The acquisition of positively charged amino acids in HBsAg C- terminus impairs HBsAg secretion, affects its structural stability and is associated with HBV-induced liver cancer 53
Hepatitis B-related hepatic flare during immune reconstitution syndrome after antiretroviral treatment initiation in an HBV surface antigen-positive patient with HIV: viroimmunological and histological characterization 51
Evidence of abundant transcriptionally active HBV-integration events involving genetic regions crucial for cell proliferation in the setting of HBeAg positive infection. 51
Neuro-Axonal Damage and Alteration of Blood–Brain Barrier Integrity in COVID-19 Patients 50
THE ENRICHMENT OF POSITIVELY CHARGED AMINO ACIDS IN HBsAg C-TERMINUS IMPAIRS HBsAg SECRETION, AFFECTS ITS STRUCTURAL STABILITY AND IS CORRELATED WITH HBV-INDUCED LIVER CANCER. 50
HIV/HBV coinfection remodels the immune landscape and natural killer cell ADCC functional responses 50
PATHWAYS UNDERLYING HDV PERSISTENCE ACT INDEPENDENTLY FROM THE EXTENT OF HBV RESEVOIR AND ARE SUSTAINED BY AN ABUNDANT PRODUCTION OF HBSAG DERIVED FROM INTEGRATED HBV-DNA P 214 49
Evidence of extensive transcriptionally active HBV integrations involving genetic regions crucial for cell proliferation in the setting of HBeAg positive infection 48
HDV INFECTION IS STABLE IN CENTRAL ITALY ACROSS THE LAST TWO DECADES AND IS CHARACTERIZED BY THE CIRCULATION OF MULTIPLE HDV SUB-GENOTYPES 1 WITH A DIFFERENT PRO-INFLAMMATORY POTENTIAL 48
KINETICS OF THE THREE HBSAG ISOFORMS ALONG WITH HDV-RNA PREDICT VIROLOGICAL RESPONSE IN CHD PATIENTS TREATED WITH BULEVIRTIDE UP TO 96 WEEKS P 215 47
Chronic HDV coinfection (CHD) is characterized by a different HBsAg isoforms composition respect to HBV mono-infection with higher middle- and large-HBs levels paralleling the replicative and cytolytic activity of HDV. 47
The transactivation of endogenous retroviruses correlates with HIV reservoir, lymphocytes activation and low CD4 count in virologically suppressed patients 44
Kinetics of the Three HBsAg Isoforms along with HDV-RNA Predict Virological Response in CHD Patients Treated with Bulevirtide for 48 Weeks 43
A peculiar HBsAg isoforms composition characterizes chronic HDV coinfection respect to HBV mono-infection, with higher middle-/large-HBs levels paralleling HDV activity. 43
Heterogeneity in the diagnostic sensitivities of HDV RNA quantification assays used in clinical practice in Italy: data from the first national quality control multicenter study. 42
Cryptic HBV activity is frequently observed among anti-HBc positive/HBsAg negative people living with HIV infection during HBV-active art and can jeopardize the full control of HIV replication. 41
Serum HBsAg and highly-sensitive HBV-DNA quantification can predict HBsAg loss after nucleos(t)ide analogue systematic discontinuation in non cirrhotic patients with chronic hepatitis B 40
Kinetics of hepatitis B virus replication in anti-HBc positive/HBsAg-negative people with HIV switching to tenofovir sparing therapy 40
Heterogeneity in the diagnostic performances of HDV RNA quantification assays used in clinical practice in Italy: results from a national quality control multicenter study. 37
Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance Profiles 37
New insights into hepatitis B virus lymphotropism: implications for HBV-related lymphomagenesis 36
Hepatitis B virus DNA integration as a novel biomarker of hepatitis B virus-mediated pathogenetic properties and a barrier to the current strategies for hepatitis B virus cure 35
Chronic HDV coinfection is characterized by a peculiar HBsAg isoforms composition respect to HBV mono-infection, with higher middle-/large-HBs levels paralleling HDV activity. 34
Transcriptionally active HBV integrations frequently occur in the early phases of chronic infection and mostly involve genetic regions crucial for cell proliferation. 34
HBsAg production from integrated HBV-DNA sustains HDV persistence in the setting of a limited or even absent HBV reservoir 34
Biological and clinical significance of classic and innovative virological parameters in the pathogenesis and in the clinical management of HBV infection 34
Different diagnostic performances of HDV RNA quantification assays used in clinical practicein Italy: results from a national quality control multicenter study. 33
Total HIV DNA and cell-associated HIV RNA viral reservoirs in PBMCs and GALT in patients on triple-ART and switching to dual-ART regimens. 32
Chronic HDV infection is sustained by an intense HBsAg production fromintegrated HBVDNA in the setting of a limited or even absent HBV reservoir. 32
HDV persistence is sustained by HBsAg mainly derived from integrated HBV-DNA and is independent from the extent of HBV reservoir 32
Pathways sustaining HDV activity act independently from the size of HBV resevoir and are fueled by an abundant expression of HBsAg from integrated HBV-DNA 32
Serum HBsAg and ddPCR HBV-DNA as predictive parameters of HBsAg loss after nucleo (s) tide analogue (NA) treatment discontinuation in non-cirrhotic patients with Chronic Hepatitis B 31
Total HIV-DNA quantification (automated Elitech InGenius platform) in antiretroviral treated people living with HIV: viro-immunological correlations 30
HBs isoforms as innovative biomarkers in predicting virological response in chronic hepatitis delta patients treated with bulevirtide monotherapy. 29
Kinetics of the three HBsAg forms along with HDV-RNA predict virological and biochemical responses in chronic hepatitis delta patients treated with bulevirtide for 48 weeks. 29
The transactivation of human endogenous retroviruses is associated with HIV-1 reservoir, lymphocyte activation and low CD4 count in virologically suppressed PLWH 27
HBs isoforms can play a role in predicting virological response in patients with chronic hepatitis delta under bulevirtide monotherapy. 21
Intrahepatic HDV Activity Is Fueled By Integrated HBV DNA-Derived HBs Independently From CccDNA Size 21
The composition of HBsAg along with HDV-RNA predicts virological response in chronic hepatitis delta patients treated with bulevirtide for 48 weeks. 20
null 3
Totale 6.590
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.488
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.488
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021278 0 0 0 0 0 53 123 59 12 11 10 10
2021/2022252 14 7 0 16 9 26 25 17 86 8 1 43
2022/2023485 31 61 44 50 53 76 33 47 38 3 35 14
2023/2024726 138 16 74 49 73 80 38 11 25 134 24 64
2024/20251.952 70 358 227 143 88 159 212 103 200 127 133 132
2025/20262.054 456 171 400 433 439 155 0 0 0 0 0 0
Totale 6.590